pCR

es-BC - HER2 negative - (neo)adjuvant (NA) breast cancer - HER2-positive es-BC - HER2 negative - (neo)adjuvant (NA)

versus paclitaxel followed by doxorubicin plus cyclophosphamide
pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamide vs. paclitaxel followed by doxorubicin plus cyclophosphamide 1 1.0better0.35.0100 %